Neutekbio

NeutekBio is a clinical-stage biotechnology company focused on developing next-generation Natural Killer (NK) cell-based immunotherapies for cancer. Headquartered in Dublin, Ireland, the company utilizes its proprietary Neutek platform to produce high-potency, off-the-shelf NK cell products designed to overcome the limitations of current cell therapies in treating solid tumors. Its lead candidate, NTB-311, is an activated NK cell therapy currently undergoing Phase 1 clinical trials for various oncological indications. NeutekBio's pipeline also includes engineered CAR-NK programs aimed at enhancing tumor specificity and persistence. The company leverages advanced manufacturing processes to ensure the scalability and consistency of its therapeutic candidates.